Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry

Part of paid clinical trials in Cary, North Carolina.

Sponsor
Duke University
Study ID
NCT04085029
Status
Recruiting
Apply to this trial

Conditions

  • Metastatic Cancer
  • Oligometastasis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.

Key Dates

Start date
Sep 26, 2019
Status verified
Feb 2026
Primary completion
Sep 30, 2029
Completion
Sep 30, 2029

Study Design

Enrollment
300 participants (estimated)

Primary Outcome Measure

Occurrence of acute adverse events following radiotherapy [ Time Frame: 90 Days ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
Duke Cancer Institute CaryCaryNorth Carolina27518
Clinical Trials Office
[email protected]
919-668-3726
Duke University Medical CenterDurhamNorth Carolina27710
Clinical Trials Office
[email protected]
919-668-3726
Durham Veterans Administration Health Care System (DVAHCS)DurhamNorth Carolina27705
Josephine Gaston, RN
[email protected]
Joseph Salama, MD (PRINCIPAL_INVESTIGATOR)
Duke Raleigh HospitalRaleighNorth Carolina27609
Clinical Trials Office
[email protected]
919-668-3726
Duke Women's Cancer Care RaleighRaleighNorth Carolina27607
Clinical Trials Office
[email protected]
919-668-3726

Find similar trials in Cary, NC

By research site
Duke Cancer Institute Cary· Cary, NCDuke University Medical Center· Durham, NCDurham Veterans Administration Health Care System (DVAHCS)· Durham, NCDuke Raleigh Hospital· Raleigh, NCDuke Women's Cancer Care Raleigh· Raleigh, NC

Related Studies